Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03330106 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT03330106 is a Phase 1 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 68 participants.
The verdict
NCT03330106, a Phase 1 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the effects of 25 and 50 milligram per square meter (mg/m\^2) pevonedistat on the Fridericia corrected QT interval (QTcF) of the electrocardiogram (ECG).
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Pevonedistat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2021-06-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03330106
The ClinicalTrials.gov registry entry for NCT03330106 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT03330106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03330106 about?
NCT03330106 is a clinical study titled "A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors". The purpose of this study is to characterize the effects of 25 and 50 milligram per square meter (mg/m\^2) pevonedistat on the Fridericia corrected QT interval (QTcF) of the electrocardiogram (ECG).
What is the current status of trial NCT03330106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2017-11-15. Estimated completion is 2021-06-21.
What interventions are being tested in trial NCT03330106?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), Pevonedistat (DRUG).
Who is sponsoring clinical trial NCT03330106?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.